Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HM, Beck K, Kupper H.

Ann Rheum Dis. 2003 Dec;62(12):1168-77.

2.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
3.

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.

Kroesen S, Widmer AF, Tyndall A, Hasler P.

Rheumatology (Oxford). 2003 May;42(5):617-21.

5.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK.

Arthritis Rheum. 2003 Jan;48(1):35-45. Erratum in: Arthritis Rheum. 2003 Mar;48(3):855.

6.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

7.

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).

Furst DE, Keystone EC, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Burmester GR, Crofford LJ, Kavanaugh A.

Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii2-5. Review.

8.

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

den Broeder AA, Joosten LA, Saxne T, HeinegÄrd D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, van de Putte LB, Barrera P.

Ann Rheum Dis. 2002 Apr;61(4):311-8.

9.

Guidelines for the management of rheumatoid arthritis: 2002 Update.

American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.

Arthritis Rheum. 2002 Feb;46(2):328-46. No abstract available.

PMID:
11840435
10.

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM.

N Engl J Med. 2001 Oct 11;345(15):1098-104.

11.

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.

Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL.

Arthritis Rheum. 2001 Sep;44(9):2009-17.

12.

Rheumatoid arthritis.

Lee DM, Weinblatt ME.

Lancet. 2001 Sep 15;358(9285):903-11. Review.

PMID:
11567728
13.
14.

Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis.

Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD.

Arthritis Rheum. 2000 Jul;43(7):1473-7.

15.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P.

Lancet. 1999 Dec 4;354(9194):1932-9.

PMID:
10622295
16.

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME.

Ann Intern Med. 1999 Mar 16;130(6):478-86.

PMID:
10075615
17.

The original "DAS" and the "DAS28" are not interchangeable: comment on the articles by Prevoo et al.

van der Heijde DM, Jacobs JW.

Arthritis Rheum. 1998 May;41(5):942-5. No abstract available.

PMID:
9588750
18.

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM.

N Engl J Med. 1997 Jul 17;337(3):141-7.

19.
20.

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, et al.

Arthritis Rheum. 1993 Jun;36(6):729-40.

PMID:
8507213
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk